Targeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662)
靶向胶质母细胞瘤干细胞的昼夜节律 (R01CA238662)
基本信息
- 批准号:10308040
- 负责人:
- 金额:$ 54.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:ARNTL geneAdjuvantAdoptedAgeAgonistAlpha RhythmAngiogenic FactorApoptosisAttenuatedBindingBiological ClocksBrainBrain NeoplasmsCarbonCaringCell Cycle ArrestCell MaintenanceCellsCellular Metabolic ProcessChemoresistanceChromatinCircadian RhythmsCitric Acid CycleClinicalCombined Modality TherapyComplexCytolysisDNA DamageDataDependenceDevelopmentDown-RegulationEnzymesEvolutionExcisionExposure toFeedbackFoundationsGenesGenetic TranscriptionGlioblastomaGliomaGlucoseHourHumanImmuneIn VitroInvadedIonizing radiationMaintenanceMalignant - descriptorMalignant NeoplasmsMediatingMetabolicMetabolic PathwayMetabolismMitochondriaMolecularNeuronsNormal CellOncogenicOperative Surgical ProceduresOralOrganismPathway interactionsPatientsPerformance StatusPlanet EarthPlanetsPrognosisProteinsRadiation therapyRecurrenceRegulationRegulatory PathwayReportingResearch Project GrantsResistanceRespirationRoleRotationSignal Transduction PathwayTestingToxic effectTranslatingTreatment FailureTricarboxylic Acidsangiogenesisbasecancer stem cellcell growthchemotherapychromatin immunoprecipitationcircadiancircadian pacemakerclinically significantconventional therapycryptochromedesigneffective therapyempoweredepigenetic regulationimprovedneoplastic cellnerve stem cellnew therapeutic targetnovelnovel therapeuticspalliationpatient responsepatient stratificationpre-clinicalradiation resistanceresponseself-renewalsmall hairpin RNAsmall moleculesmall molecule inhibitorstemstem cell biologystem cell differentiationstem cell growthstem cell proliferationstem cell self renewalstem cellsstem-like cellstemnesstargeted agenttemozolomidetherapeutically effectivetherapy resistanttranscription factortreatment responsetumor
项目摘要
Glioblastomas rank among the most lethal of all human cancers. Current therapy includes maximal surgical
resection, followed by combined radiotherapy and oral chemotherapy (temozolomide), and adjuvant
temozolomide. Maximal current therapy offers only palliation. Median survival for glioblastoma patients has
been reported to be 15-21 months, but these data are derived from patients with favorable age and
performance status. Recurrent glioblastoma therapy is limited with little evidence for effective therapy.
Treatment failure is derived from numerous causes, including the presence of stem-like tumor cells, called
glioblastoma stem cells (GSCs). GSCs contribute to radioresistance, chemoresistance, invasion, immune
escape, and angiogenesis. GSCs display dependencies on specific signal transduction pathways and
epigenetic regulation, associated with metabolic reprogramming.
Almost all living organisms on earth are exposed to a regular 24-hour day-night cycles generated by planet’s
rotation around its own axis, which in return leads to the evolution of intrinsic, entrainable circadian rhythm
driven by cell autonomous biological clocks. Molecular oscillation of transcriptional circuitry to regulate
circadian rhythms include positive regulation by the BMAL1 and CLOCK transcription factors, with two
negative regulatory loops that either transcriptionally downregulate BMAL1 or bind and inhibit
BMAL1:CLOCK transcriptional complexes. In our proposed studies, we leverage preliminary findings that the
circadian rhythm machinery serves distinct cellular and molecular roles in maintenance of GSCs. We will
determine the necessity for circadian rhythm regulation in GSCs mediate through metabolic reprogramming
and selective activation of oncogenic pathways.
To translate these efforts into novel clinical paradigms, we are using a novel class of agents that target
circadian clock function. These small molecule inhibitors are brain penetrant and can be combined with other
therapies to create synergistic targeting of GSCs. To generate the most effective therapeutic paradigm, we
will interrogate the preclinical utility of novel targeted therapies that disrupt the circadian rhythm oscillatory
loop that could accentuate the efficacy of conventional therapy. Collectively, the proposed studies will lay
the foundation for improved understanding of circadian rhythm regulation in cancer stem cell biology with
possible application to improved oncologic care.
胶质母细胞瘤是所有人类癌症中最致命的。目前的治疗包括最大限度的手术
切除术,然后联合放疗和口服化疗(替莫唑胺),以及辅助
替莫唑胺最大电流疗法只能缓解症状。胶质母细胞瘤患者的中位生存期
据报告为15-21个月,但这些数据来自年龄有利的患者,
性能状态。复发性胶质母细胞瘤的治疗是有限的,几乎没有证据表明有效的治疗。
治疗失败的原因有很多,包括存在干细胞样肿瘤细胞,称为
胶质母细胞瘤干细胞(GSC)。GSC有助于辐射抗性、化学抗性、侵袭、免疫耐受性和免疫耐受性。
逃逸和血管生成。GSC显示出对特定信号转导途径的依赖性,
表观遗传调控,与代谢重编程有关。
地球上几乎所有的生物体都暴露在由行星的
围绕自己的轴旋转,这反过来导致内在的,可重复的昼夜节律的进化
由细胞自主生物钟驱动。转录回路的分子振荡调节
昼夜节律包括BMAL 1和CLOCK转录因子的正调控,其中两个
负调控环,其要么转录下调BMAL 1,要么结合并抑制
BMAL 1:时钟转录复合物。在我们提出的研究中,我们利用初步发现,
昼夜节律机制在维持GSC中发挥不同的细胞和分子作用。我们将
确定通过代谢重编程介导的GSC昼夜节律调节的必要性
和选择性激活致癌途径。
为了将这些努力转化为新的临床范例,我们正在使用一类新的药物,
生物钟功能这些小分子抑制剂是脑渗透剂,并且可以与其他药物组合。
这些疗法可以产生GSC的协同靶向作用。为了产生最有效的治疗模式,我们
将询问新型靶向治疗的临床前效用,
可以增强传统疗法的疗效。总体而言,拟议的研究将奠定
癌症干细胞生物学中昼夜节律调节的基础,
可能应用于改善肿瘤护理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVE A KAY其他文献
STEVE A KAY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVE A KAY', 18)}}的其他基金
Targeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662)
靶向胶质母细胞瘤干细胞的昼夜节律 (R01CA238662)
- 批准号:
10419142 - 财政年份:2021
- 资助金额:
$ 54.32万 - 项目类别:
Targeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662)
靶向胶质母细胞瘤干细胞的昼夜节律 (R01CA238662)
- 批准号:
10530615 - 财政年份:2021
- 资助金额:
$ 54.32万 - 项目类别:
Targeting the Circadian Rhythm in Glioblastoma Stem Cells
针对胶质母细胞瘤干细胞的昼夜节律
- 批准号:
9888132 - 财政年份:2019
- 资助金额:
$ 54.32万 - 项目类别:
Targeting the Circadian Rhythm in Glioblastoma Stem Cells
针对胶质母细胞瘤干细胞的昼夜节律
- 批准号:
10061578 - 财政年份:2019
- 资助金额:
$ 54.32万 - 项目类别:
The Role of Cryptochromes in Circadian Regulation of Metabolism
隐花色素在代谢昼夜节律调节中的作用
- 批准号:
9342896 - 财政年份:2016
- 资助金额:
$ 54.32万 - 项目类别:
The Role of Cryptochromes in Circadian Regulation of Metabolism
隐花色素在代谢昼夜节律调节中的作用
- 批准号:
9175163 - 财政年份:2016
- 资助金额:
$ 54.32万 - 项目类别:
Role of Ror proteins in the mammalian circadian clock
Ror 蛋白在哺乳动物生物钟中的作用
- 批准号:
7204152 - 财政年份:2006
- 资助金额:
$ 54.32万 - 项目类别:
Role of Ror proteins in the mammalian circadian clock
Ror 蛋白在哺乳动物生物钟中的作用
- 批准号:
8656526 - 财政年份:2006
- 资助金额:
$ 54.32万 - 项目类别:
Role of Ror proteins in the mammalian circadian clock
Ror 蛋白在哺乳动物生物钟中的作用
- 批准号:
7390286 - 财政年份:2006
- 资助金额:
$ 54.32万 - 项目类别:
Role of Ror proteins in the mammalian circadian clock
Ror 蛋白在哺乳动物生物钟中的作用
- 批准号:
8328724 - 财政年份:2006
- 资助金额:
$ 54.32万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 54.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 54.32万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 54.32万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 54.32万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 54.32万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 54.32万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 54.32万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 54.32万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 54.32万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 54.32万 - 项目类别: